Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.

Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL.

ESC Heart Fail. 2018 Jun 19. doi: 10.1002/ehf2.12308. [Epub ahead of print]

PMID:
29916559
2.

Echocardiography and Survival in Light Chain Cardiac Amyloidosis: Back to Basics.

Siddiqi OK, Sanchorawala V, Ruberg FL.

Circ Cardiovasc Imaging. 2018 May;11(5):e007826. doi: 10.1161/CIRCIMAGING.118.007826. No abstract available.

PMID:
29752394
3.

Native T1 and Extracellular Volume in Transthyretin Amyloidosis.

Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, Treibel TA, Whelan CJ, Knight DS, Kellman P, Ruberg FL, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2018 Mar 12. pii: S1936-878X(18)30198-0. doi: 10.1016/j.jcmg.2018.02.006. [Epub ahead of print]

PMID:
29550324
4.

Once AL amyloidosis: not always AL amyloidosis.

Jhaveri T, Sarosiek S, Ruberg FL, Siddiqi O, Berk JL, Sanchorawala V.

Amyloid. 2018 Mar 8:1-2. doi: 10.1080/13506129.2018.1449104. [Epub ahead of print] No abstract available.

PMID:
29516761
5.

Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.

Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, Connors LH.

Circ Heart Fail. 2018 Feb;11(2):e004000. doi: 10.1161/CIRCHEARTFAILURE.117.004000.

PMID:
29449366
6.

Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).

Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, Sarosiek S.

Amyloid. 2018 Mar;25(1):62-67. doi: 10.1080/13506129.2018.1436048. Epub 2018 Feb 9.

PMID:
29424556
7.

More Than Meets the Eye: Time for a New Imaging Paradigm to Test for Cardiac Amyloidosis.

Maurer MS, Ruberg FL, Weinsaft JW.

J Card Fail. 2018 Feb;24(2):87-89. doi: 10.1016/j.cardfail.2017.12.006. Epub 2018 Jan 3. No abstract available.

PMID:
29305971
8.

Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure.

Arvanitis M, Chan GG, Jacobson DR, Berk JL, Connors LH, Ruberg FL.

Amyloid. 2017 Dec;24(4):253-255. doi: 10.1080/13506129.2017.1391086. Epub 2017 Oct 20. No abstract available.

PMID:
29052438
9.

Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.

Siddiqi OK, Ruberg FL.

Trends Cardiovasc Med. 2018 Jan;28(1):10-21. doi: 10.1016/j.tcm.2017.07.004. Epub 2017 Jul 13. Review.

PMID:
28739313
10.

Challenging the myths of cardiac amyloidosis.

Siddiqi OK, Ruberg FL.

Eur Heart J. 2017 Jun 21;38(24):1909-1912. doi: 10.1093/eurheartj/ehx210. No abstract available.

PMID:
28444296
11.

Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016.

Maurer M, Lousada I, Hanna M, Ruberg F, Mohty D, Dispenzieri A, Liedtke M, Paulson I, Vest J, Grogan M.

Amyloid. 2017 Mar;24(sup1):165-166. doi: 10.1080/13506129.2017.1286582. No abstract available.

PMID:
28434366
12.

Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis.

Arvanitis M, Simon S, Chan G, Fine D, Beardsley P, LaValley M, Jacobson D, Koch C, Berk JL, Connors LH, Ruberg FL.

Amyloid. 2017 Mar;24(sup1):120-121. doi: 10.1080/13506129.2017.1295371. No abstract available.

13.

Cardiac Amyloidosis: A Zebra Hiding in Plain Sight?

Ruberg FL.

Circ Cardiovasc Imaging. 2017 Mar;10(3):e006186. doi: 10.1161/CIRCIMAGING.117.006186. Epub 2017 Mar 15. No abstract available.

14.

Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.

Arvanitis M, Koch CM, Chan GG, Torres-Arancivia C, LaValley MP, Jacobson DR, Berk JL, Connors LH, Ruberg FL.

JAMA Cardiol. 2017 Mar 1;2(3):305-313. doi: 10.1001/jamacardio.2016.5864.

16.

Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis.

Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL.

Eur Heart J Cardiovasc Imaging. 2017 Sep 1;18(9):1057-1064. doi: 10.1093/ehjci/jew298.

PMID:
27965280
17.

Should Histologic Determination of Amyloid Load Determine Management Decisions in Light-Chain Amyloidosis?

Ruberg FL, Fontana M, Gillmore JD.

J Am Coll Cardiol. 2016 Dec 6;68(22):2493-2494. doi: 10.1016/j.jacc.2016.07.786. No abstract available.

18.

Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis?

Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL.

JACC Cardiovasc Imaging. 2017 Jun;10(6):713-714. doi: 10.1016/j.jcmg.2016.06.003. Epub 2016 Aug 24. No abstract available.

19.

Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.

Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS.

JAMA Cardiol. 2016 Nov 1;1(8):880-889. doi: 10.1001/jamacardio.2016.2839.

PMID:
27557400
20.

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN.

Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.

Supplemental Content

Loading ...
Support Center